REGULATORY RELIANCE AND RECOGNITION FOR MEDICAL DEVICE PREMARKET REGISTRATION

Presenter:
Ms. Joanna KOH
MDNet.Regulatory Consultants
AHWP Playbook Lead Trainer

Hosted By
SULTANATE OF OMAN
Ministry of Health
DG of Pharmaceutical Affairs & Drug Control
Bibliography
Mrs. Joanna Koh

Past Director / Senior Regulatory Consultant in Medical Devices Branch & Compliance Branch in the Health Sciences Authority of Singapore for 8 years (2008-2016). Lead in the implementation of the MD regulations in 2012.

She is currently managing her own business MDNet.Regulatory Consultants, as its Principal Consultant

Co-Chair of the ASEAN Medical Device Working Group, (2008-2014) working on the ASEAN MD Directive up to its ministerial agreement in 2014

Chair in the AHWP-TC for 6 years (2008-2014) & current Advisor to Post Market Workgroup.

Trainer and Facilitator for Capacity Building Programs, conducted by WHO, EU Gateway, Centre of Reg Excellence (CORE), MDRA (Nat U of Spore), and in ASEAN and AHWP member economies including Kazakhstan, Myanmar, Thailand and Vietnam.
Disclaimer

“The opinions expressed in this presentation and on the following slides are solely those of the presenter.

The presenter makes no warranty, express or implied, that the statements made are correct, and will not require modification as experience and technological advances dictate, or will be suitable for any purpose or workable in any application, or otherwise. The presenter do not assume any liability whatsoever for the accuracy and completeness of the information presented”

Joanna Koh
Scope of presentation

CONSIDERATIONS:

- **Definitions**
- **Principles & Requirements**
- **Applications**
  - *Expedited Routes of Reviews*
- **Examples**
Definitions

For a more comprehensive list of definitions, please refer to:
Good Regulatory Practice (GRP) – points for consideration

❖ Good regulatory practices (GRP) provide a means for establishing sound, affordable and effective regulation of medical products
  ➢ A set of practices that are to be applied to the development, implementation and maintenance of controls
  ➢ including laws, regulations and guidelines – in order to achieve a public policy objective
  ➢ achieve a public policy objective

❖ REGULATIONS should be -
  ➢ sufficiently flexible to allow for a rational response to changes e.g. new technologies, emergencies, shortages etc
  ➢ language should be descriptive and not prescriptive

❖ Regulatory system should provide the flexibility to apply good judgement within the regulatory framework.

❖ inefficient regulatory systems can be a barrier to access to safe, effective and quality Medical products
Regulatory Cooperation

❖ A practice between NRAs aimed at efficiently regulating medical products.
❖ Or by agency or institution or on a government-wide basis.
❖ Formal mechanisms can include the creation of
  ▪ joint institutions and treaties and conventions such as MRAs, or
  ▪ sharing of information, scientific collaboration, common risk assessment, joint reviews, and development of standards.
❖ Can include work with international counterparts to build regulatory capacity or provide technical assistance building the improvement of international regulatory governance practices
**Regulatory Convergence ; Regulatory Harmonization**

**Regulatory convergence:**
- a voluntary process whereby the regulatory requirements in different countries or regions become more similar or “aligned” over time, which will result
  - *from the gradual adoption of internationally recognized technical guideline documents, standards and scientific principles, common or similar practices and procedures, or*
  - *In the establishment of appropriate domestic regulatory mechanisms that align with shared principles to achieve a common public health goal*

**Regulatory harmonization**
- the process by which technical guidelines are developed in order to be uniform across participating authorities in multiple countries
Regulatory Recognition

❖ **The routine acceptance** by the NRA in one jurisdiction of the regulatory decision of another NRA or other trusted institution.

❖ Recognition indicates that **evidence of conformity** with the regulatory requirements of country A is sufficient to meet the regulatory requirements of country B.

❖ Recognition may be **unilateral or multilateral**, 

❖ May be the subject of **a mutual recognition agreement**.
Regulatory Reliance

- The act whereby the **NRA in one jurisdiction** may take into account and give significant weight to (totally or partially) **rely upon evaluations performed by another NRA or trusted institution in reaching its own decision**

- **A practice between NRAs** aimed at efficiently regulating medical products.

**NOTE:** *The relying authority remains responsible and accountable for decisions taken, even when it relies on the decisions and information of others*
Putting it in place
A Stepwise approach, harmonization, reliance, recognition

- Reliance and recognition:
  - National responsibilities
  - International collaboration
  - Basic-level controls and their enforcement

- Publish law, including definition, and regulations with transition period
  - Establish medical device classification for regulatory purposes
  - Establish Essential Principles of safety and performance
  - Basic-level controls and enforcement – premarket
  - Establish a basis for reliance and recognition
  - Establish requirements for declaration of conformity
  - Establish requirement for manufacturers to have a QMS
  - Establish requirements for labels and labelling
  - Prohibit deceptive, misleading and false advertising
  - Establish provisions for exceptional premarket situations

Source: WHO
<table>
<thead>
<tr>
<th>Basic level controls and enforcement</th>
<th>Premarket</th>
<th>Placing on the market</th>
<th>Postmarket</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Premarket</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Publish law, including definition, and regulations with transition period</td>
<td></td>
<td>- Registration of establishments</td>
<td>- Establish a system for vigilance reporting</td>
</tr>
<tr>
<td>- Establish medical device classification for regulatory purposes</td>
<td></td>
<td>- Listing of medical devices</td>
<td>- Require mandatory notification by the manufacturer of field safety corrective actions</td>
</tr>
<tr>
<td>- Establish Essential Principles of safety and performance</td>
<td></td>
<td>- Import controls</td>
<td>- Establish a procedure to withdraw unsafe medical devices from the market</td>
</tr>
<tr>
<td>- Establish basis for reliance and recognition</td>
<td></td>
<td></td>
<td>- Establish procedure to issue safety alerts to users</td>
</tr>
<tr>
<td>- Establish requirements for declaration of conformity</td>
<td></td>
<td></td>
<td>- Undertake market surveillance</td>
</tr>
<tr>
<td>- Establish requirement for manufacturers for a QMS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Establish requirements for labels and labelling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Prohibit deceptive, misleading and false advertising</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Establish provisions for exceptional premarket situations</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: WHO
The comprehensive table of contents is a complete list of all documents in the dossier, arranged by Module, and with location references for each document. Specify the titles of studies in the table of contents, indicating the type of study and topic in the title.

The Regulated Product Submission (RPS) - the objective of establishing a internationally agreed, comprehensive harmonized file structure for premarket medical device submissions

PURPOSE:
- *To create a comprehensive submission structure that can be used as a harmonized international electronic submission format to the NRA for market authorization.*
- *To minimize regional divergences and indicating where regional variation exists.*
Essential Principles Requirement is a principle component in the ToC harmonized dossier

- IMDRA guidance document provides a harmonized Essential Principles, covering
  - Common set of fundamental design and manufacturing requirements of medical devices /IVDs to ensure safety and performance as intended and are met.

- Worldwide adoption of this common set will have significant benefits to manufacturers, users, patients/consumers, and to Regulatory Authorities.

- It will reduce differences between jurisdictions and decreases the cost of gaining regulatory compliance and

- allows patients earlier access to new technologies and treatments.

- Adoption of this document’s recommendation will support global convergence of regulatory systems
  - There will be a consistent, economic and effective approach to the control of MDs and the interest of public health
  - There will be a balance between the responsibilities of RAs to safeguard the health of their citizens and avoid placing unnecessary burdens upon the industry.
Many jurisdictions (apart from the GHTF founding members) use the STED or CSDT template.

Co-relation and mapping of the 2 templates example:-

### CSDT AND STED – COMPARISON

- STED is GHTF format (Australia, Canada, EU, Japan, USA)
- STED and CSDT are similar.

<table>
<thead>
<tr>
<th>Sect.</th>
<th>Heading</th>
<th>Sect.</th>
<th>Heading</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>Executive Summary</td>
<td>9.0</td>
<td>Essential Principles</td>
</tr>
<tr>
<td>4.1</td>
<td>Essential Principles</td>
<td>6.0-6.2</td>
<td>Device Description and Product Specification</td>
</tr>
<tr>
<td>4.2</td>
<td>Device Description</td>
<td>6.3</td>
<td>Reference to similar and previous generations</td>
</tr>
<tr>
<td>4.3</td>
<td>Design Verification and Validation</td>
<td>11.0-11.8</td>
<td>Product Verification &amp; Validation</td>
</tr>
<tr>
<td>4.4</td>
<td>Labeling</td>
<td>7.0</td>
<td>Labeling</td>
</tr>
<tr>
<td>4.5</td>
<td>Risk Analysis</td>
<td>10.0</td>
<td>Risk Analysis &amp; Control Summary</td>
</tr>
<tr>
<td>4.6</td>
<td>Manufacturer’s Information</td>
<td>8.1</td>
<td>Device Design Stages</td>
</tr>
<tr>
<td></td>
<td>AMDD Annex 6: Declaration of Conformity</td>
<td>8.2-8.3</td>
<td>Manufacturing Information</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13.0</td>
<td>Declaration of Conformity</td>
</tr>
<tr>
<td>Executive Summary</td>
<td>CSDT</td>
<td>STED</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>An executive summary shall be provided with the CSDT, which shall include the following information: &lt;ul&gt;&lt;li&gt;an overview, e.g., introductory descriptive information on the medical device, the intended uses and indications for use of the medical device, any novel features and a synopsis of the content of the CSDT;&lt;/li&gt;&lt;li&gt;commercial marketing history;&lt;/li&gt;&lt;li&gt;intended uses and indications in labelling;&lt;/li&gt;&lt;li&gt;list of regulatory approval or marketing clearance obtained;&lt;/li&gt;&lt;li&gt;status of any pending request for market clearance; and&lt;/li&gt;&lt;li&gt;important safety/ performance related information.&lt;/li&gt;&lt;/ul&gt;</td>
<td>No requirement for an Executive Summary in STED</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Reference to similar and previous generations of device. | Where relevant to demonstrating conformity to the Essential Principles, and |
### TABLE 1 – SUMMARY OF SUBMISSION REQUIREMENTS

<table>
<thead>
<tr>
<th>MEDICS Application Form - Dossier &amp; Supporting Document(s)</th>
<th>Reference technical documents</th>
<th>Class B</th>
<th>Class C &amp; D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Annex 2 List of Configurations</td>
<td>CH1.05 Listing of Device(s)</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>3. Proof of reference agency’s approval(s)</td>
<td>CH1.07 Free Sale Certificate; Certificate of Marketing authorization</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>4. Proof of marketing history in the reference agencies’ jurisdictions e.g. Invoice with date, proof of sale or a declaration on marketing history</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>5. Declaration of no safety issues globally</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>6. Executive Summary</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
</tbody>
</table>
What’s Next?
Principles/parameters to consider for good governance in regulatory reliance, recognition practices

- To decide whether to use either the reliance or recognition option, NRA must have
  - have clear understanding of the regulatory system that applies within the country where the medical device is manufactured. (Export only MD may have less reg requirements like labelling)
  - note that sometimes devices may have different configurations for different markets; these may vary in aspects such as the intended use, site of manufacture, power supply, labelling language and applied quality control,
  - note specifically for IVDs, market access review is complex, due wide variance in classification and scrutiny of IVDs in many countries. (e.g. in the EU Directive, independent assessment could mean that most IVDs bearing a CE mark are self-assessed by the manufacturer)

In general, where a NRA relies upon information from a counterpart in another jurisdiction, it must first establish confidence in the counterpart authority and reach agreement on the exchange of confidential information.
Examples: Countries practising Regulatory Reliance, Recognition (some info) ……

- Australia (Therapeutic Goods Authority - TGA)
- Singapore (Health Sciences Authority - HSA)
- Thailand (Thai Food and Drug Authority - TFDA)
- Malaysia (Medical Device Authority – MDA)
- Vietnam (Dept of Medical Equipment & Construction – DMEC)
EU-Australia MRA (Mutual Recognition Agreements) on conformity assessment.

■ Background on the MRA
  - Both the European Union and Australia recognise and accept the technical competence of each other's conformity assessment bodies (CABs) to certify products for compliance with the regulatory requirements of the other Party, largely eliminating the need for duplicative testing or re-certification when the goods are traded.
  - Came into force in 1999 and was the first fully operational MRA of its type in the world

■ To be amended the current EU-Australia MRA and came into force on 1 January 2013.
EU-Australia Amended MRA

- Changes in place (AMENDED MRA)
  - Contributory Factor - The new EU Medical Device Regulations, in May 2017 and with full application of the MDR coming into effect on the 26th May 2020.
    - simplifying the administration of the MRA,
    - A number of amendments in which the MRA applies e.g.
    - A 'rule of origin' clause (which stipulates that only those products manufactured in the European Union or Australia are covered by the MRA) has been removed and replaced with a more specific clause in the medical devices with
      - Activities such as repairing, reconditioning, refurbishment, labelling, packaging, quality control inspections alone, or sterilisation alone, will be specifically excluded from the definition of ‘manufacture’.
  - Radioactive medical devices of lower risk classes will be included in the MRA.
  - Exclude a number of high risk medical devices from the MRA, MD with medicines, barrier contraceptives until confidence building activities are carried out by both Parties
  - Others

Example of the Regulatory Reliance:
- Singapore (HSA) / Thailand (TFDA) / Vietnam and Malaysia

Types of registration submission routes
- Abridged, Expedited and Immediate evaluation (Singapore)
- Concise evaluation route (Thailand)

Reference NRAs:
- Australia Therapeutic Goods Administration (TGA) Device Registration Licence
- Health Canada (HC) Device Registration Licence
- Japan Ministry of Health, Labour and Welfare (MHLW)
- US Food and Drug Administration (US FDA) 510K clearance, PMA approval
- European Union Notified Bodies (EU NB) via EC certificates
  For Singapore, further info on types of EC certificates available on HSA website

Approvals from EU and TGA will qualify as independent reference regulatory agency’s approval only if the devices have been reviewed and approved by the respective agencies and the devices are not registered based on the Mutual Recognition Agreement (MRA)
HSA Evaluation Route Class B (Example)

Abridged

- (i) A medical device that has obtained at least one reference regulatory agency approval for a labelled use *identical* to that intended for marketing in Singapore at the point of submission will qualify for the abridged evaluation route.

Immediate

- (ii) As abridged requirement PLUS

- (iii) Marketed for at least three years **Or** the medical device has been marketed in Singapore for 3 years *(w evidence)*

- (iv) No safety issues globally associated with the use of the medical device(s) when used as intended by the product owner, in the last three years *(details defined in Website)*

- (v) No prior rejection/withdrawal

*Alternative to (ii) and (iii)*

- Approvals by at least two of HSA’s independent reference regulatory agencies for a labelled use identical to that intended for marketing in Singapore;

Source: SEE details GN15 @HSA Website,
HSA Evaluation Route Class C & D (Example)

- (i) Full Evaluation Route (no prior approval from recognized RAs)
- (ii) Abridged Evaluation Route
- (iii) Expedited Evaluation Route
  - a. Expedited Class C Registration (ECR)
  - b. Expedited Class D Registration (EDR)
- (iv) Immediate Class C Registration (ICR) Evaluation Route [solely for Standalone Medical Mobile Application]

For more details, please refer to HSA Website,
Concise Evaluation Route

QUALIFICATION

To qualify for Concise Evaluation, a medical device must be registered (through full evaluation) and marketed for more than one year without any serious adverse events in 2 of 5 reference markets listed below; or

- in 1 of the markets for at least three years.

1. Australia: Therapeutic Good Administration (TGA)
2. Canada: Health Canada (HC)
3. European Union: Notified Body (EU NB)
5. USA: Food and Drug Administration (FDA)

For more details, please refer to TFDA Website,
Simplified Verification Assessment (SV)

■ QUALIFICATION

Premarket submissions for Class B, C and D can qualify for SA Route if the local or foreign manufacturer have obtained prior medical device registration approval from at least one of the five GHTF countries –

1. Canada: Health Canada (HC)
2. European Union: Notified Body (EU NB)
4. USA: Food and Drug Administration (FDA)
5. Australia TGA

■ The SV route is a much simpler pathway of assessment vs the full conformity extensive assessment

For more details, please refer to MDA Website,
Vietnam DMEC (MOH) – FAST Track Evaluation Route for Medical Devices

According to the new Decree passed in Vietnam early 2019, MoH will allow:
- A **Fast Track route** for all MD product licenses for Class B, C, D, with the following qualifications:
  - The MD have been registered in at least two (2) of the GHTF countries: Japan, United States, Canada, Australia, EU countries.
  - The medical device has been sold in Vietnam prior to the 31 December 2018, and:
  - The medical device has been available for sale in Vietnam for at least three (3) years within five (5) years of the submission date
  - No notifiable safety/operation issues of the medical device have been reported

For more details, please refer to Vietnam DMEC (MOH) Website,
Main Source References:

WHO Guidelines – Good Regulatory Practice / Model Regulatory Framework
IMDRF Guidance Documents
HSA Singapore – Guidance Documents
Thank You for listening